Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 May 17;19(9):560–569. doi: 10.1016/j.clml.2019.05.001

Table 1.

Details of the mCBAD (modified Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone) regimen - 28-day cycle.

Cyclophosphamide 350 mg/m2 IV every 12 hours, days 1–4
Mesna 400 mg/m2 IV every 12 hours, days 1–4
Bortezomib 1.3 mg/m2 sc/IV* days 1,4,8,11
Doxorubicin 9 mg/m2 IV continuous infusion, days 1–4
Dexamethasone 40 mg po daily on days 1–4, 9–12, 17–20

IV: intravenous; sc: subcutaneous; po: per os.

*

prior to 2012, patients received bortezomib intravenously because bortezomib was not approved as subcutaneous injection